Insys drug candidate an Orphan Drug for brain cancer

The FDA designates Insys Therapeutics' (NASDAQ:INSY) pharmaceutical cannabidiol (CBD) an Orphan Drug for the treatment of glioblastoma multiforme, the most common and most aggressive form of brain tumor in humans.

Previously, the agency designated CBD an Orphan Drug for Lennox-Gastaut Syndrome and Dravet Syndrome.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs